Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | CES2 | O00748 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | PDE2A | O00408 | 3/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.46 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29499840 | 1.00 | GAA (0.58) | GAACES2KDM4EALDH1A1HPGD | |
| SCHEMBL18290646 | 0.87 | GAA (0.45) | GAACES2KDM4EALDH1A1HPGD | |
| SCHEMBL17732180 | 0.86 | KIF11 (0.54) | GAACES2KDM4EALDH1A1HPGD | |
| SCHEMBL25376853 | 0.85 | GAA (0.44) | GAACES2KDM4EALDH1A1HPGD | |
| SCHEMBL29786688 | 0.85 | CES2 (0.52) | GAACES2KDM4EALDH1A1HPGD | |
| SCHEMBL26804966 | 0.85 | NR1H4 (0.46) | GAACES2ALDH1A1HPGDHSD17B10 | |
| SCHEMBL2073688 | 0.85 | CES2 (0.52) | GAACES2KDM4EALDH1A1HPGD | |
| SCHEMBL21852902 | 0.84 | CES2 (0.55) | GAACES2KDM4EALDH1A1HPGD | |
| SCHEMBL28188798 | 0.84 | GAA (0.57) | GAACES2KDM4EALDH1A1HPGD | |
| SCHEMBL30820 | 0.83 | CES2 (0.50) | GAACES2KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113501787-A | Method for synthesizing 6-trifluoromethyl-3-methylindazole | 黑龙江省科学院石油化学研究院 | 2021-10-15 | — | — | CN | claimed |
| EP-4021901-B1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2025-09-24 | — | — | EP | disclosed |
| US-12325702-B2 | ATF6 inhibitors and uses thereof | ALTOS LABS, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| US-20250145596-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2025-05-08 | — | — | US | disclosed |
| US-20250099431-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2025-03-27 | — | — | US | disclosed |
| EP-4523751-A2 | GLP-1R MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-4097097-B1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-01-15 | — | — | EP | disclosed |
| US-20240400563-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-12-05 | — | — | US | disclosed |
| US-20240368177-A1 | 5-AMINO-6,8-DIHYDRO-1H-FURO[3,4-d]PYRROLO[3,2-b]PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 | BEIGENE SWITZERLAND GMBH (CH) | 2024-11-07 | — | — | US | disclosed |
| US-12121511-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-10-22 | — | — | US | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| WO-2007017169-A1 | PHENYLPYRIDINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-15 | — | — | WO | disclosed |
| US-20070032530-A1 | Phenylpyridine derivatives | HOFFMANN-LA ROCHE INC. | 2007-02-08 | — | — | US | disclosed |
| EP-1740568-A2 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF CARDIOVASCULAR DISEASE. | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005077926-A2 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-25 | — | — | WO | disclosed |
| EP-0735142-B1 | Process for producing (R)-styrene oxides | SUMIKA FINE CHEMICALS CO LTD (JP) | 2001-10-24 | — | — | EP | disclosed |
| US-5717116-A | TREATING A MIXTURE OF PHENYLHALOGENOMETHYLCARBINOLS WITH A LIPASE IN THE PRESENCE OF A CARBOXYLATE FOLLOWED BY CYCLIZATION WITH A BASE | SUMIKA FINE CHEMICALS COMPANY, LIMITED (JP) | 1998-02-10 | — | — | US | disclosed |
| EP-0735142-A2 | Process for producing (R)-styrene oxides | SUMIKA FINE CHEMICAL COMPANY, LTD. (JP) | 1996-10-02 | — | — | EP | disclosed |
| US-4957934-A | AROMATASE INHIBITORS, TREATMENT OF STEROID HORMONE DEPENDENT DISEASES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-09-18 | — | — | US | disclosed |
| EP-0145314-A1 | Antifungal triazole compound | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12325702-B2 | ATF6 inhibitors and uses thereof | ATF4, XBP1, ATF1 | GAA 214/4885CES2 2791/4885KDM4E 4305/4885 |
| US-20070032530-A1 | Phenylpyridine derivatives | CYP3A5, QDPR, DPYD | GAA 636/4885CES2 1274/4885KDM4E 2121/4885 |
| US-20240400563-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | GAA 2403/4885CES2 4254/4885KDM4E 1828/4885 |
| US-12121511-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | GAA 1029/4885CES2 3448/4885KDM4E 2208/4885 |
| US-20250099431-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | GAA 1029/4885CES2 3448/4885KDM4E 2208/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | GAA 4203/4885CES2 4820/4885KDM4E 2562/4885 |
| US-20240368177-A1 | 5-AMINO-6,8-DIHYDRO-1H-FURO[3,4-d]PYRROLO[3,2-b]PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 | PRMT5, PRMT6, PRMT1 | GAA 3919/4885CES2 4679/4885KDM4E 51/4885 |
| US-20250145596-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | GAA 928/4885CES2 3337/4885KDM4E 3629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.